Trade OXFORD BIOMEDICA PLC ORD 50P - OXB CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.032
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment£1,000.00Overnight funding adjustmentCharges from full value of position-0.021276 %(-£1.06)Trade size with leverage ~ £5,000.00Money from leverage ~ $£4,000.00Go to platform: -0.02128%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment£1,000.00Overnight funding adjustmentCharges from full value of position-0.000642 %(-£0.03)Trade size with leverage ~ £5,000.00Money from leverage ~ $£4,000.00Go to platform: -0.00064%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: GBP
• Min traded quantity: 1
• Margin: 20.00%
• Stock exchange: Great Britain
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: £1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021276 %
  (-£1.06)

• Margin. Your investment: £1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000642 %
  (-£0.03)

Key Stats

• Prev. Close: 5.444
• Open: 5.404
• 1-Year Change: -11.74%
• Day's Range: 5.294 - 5.444

Trade OXFORD BIOMEDICA PLC ORD 50P - OXB

About Oxford BioMedica plc

Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Financial summary

BRIEF: For the six months ended 30 June 2021, Oxford BioMedica plc revenues increased from £34M to £81.3M. Net income totaled £18.1M vs. loss of £6.7M. Revenues reflect Europe segment increase from £19M to £70.3M. Net Income reflects Platform segment income totaling £24.4M vs. loss of £3.1M. Basic Earnings per Share excluding Extraordinary Items increased from -£0.09 to £0.22.

Equity composition

10/2003, Rights Issue, 27 new shs for every 50 shs held @ GBP 0.17 (Fct:1.54). 03/2001, Rights Issue, 1 new share for every 9 shs held @ GBP 0.55 (Fct:1.111111). 03/1998, Rights Issue, 1 new share for every 4 shs held @ GBP 0.10 (Fct:1.076). 05/2014, Priority Issue, 1 new shares for every 5 shares held @ GBp 2 (Factor:1).